Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dyax Corp
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
As Sandoz tries to assist African Union member states by selling its pandemic response portfolio medicines for zero profit, mAbxience has partnered with AstraZeneca to produce a vaccine. And CDMO Hovione has struck a deal with Ligand to boost manufacturing of Captisol, a critical ingredient for Gilead’s remdesivir.
Drug Discovery Tools
- Molecular Diversity
- Large Molecule